Example of Advances in Therapy format
Recent searches

Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format Example of Advances in Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Advances in Therapy — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Pharmacology (medical) #58 of 246 up up by 20 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 934 Published Papers | 5034 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 13/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 6.4
SJR: 1.187
SNIP: 1.192
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.1
SJR: 1.333
SNIP: 1.061
open access Open Access

SAGE

Quality:  
High
CiteRatio: 4.8
SJR: 1.164
SNIP: 1.22
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.3
SJR: 1.196
SNIP: 1.603

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

3.871

19% from 2018

Impact factor for Advances in Therapy from 2016 - 2019
Year Value
2019 3.871
2018 3.26
2017 3.085
2016 2.709
graph view Graph view
table view Table view

5.4

8% from 2019

CiteRatio for Advances in Therapy from 2016 - 2020
Year Value
2020 5.4
2019 5.0
2018 4.6
2017 4.2
2016 4.3
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 19% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 8% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.097

12% from 2019

SJR for Advances in Therapy from 2016 - 2020
Year Value
2020 1.097
2019 0.979
2018 1.037
2017 1.075
2016 0.974
graph view Graph view
table view Table view

1.429

4% from 2019

SNIP for Advances in Therapy from 2016 - 2020
Year Value
2020 1.429
2019 1.371
2018 1.268
2017 1.038
2016 1.119
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 12% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 4% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Advances in Therapy

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

Advances in Therapy

Advances in Therapy is an international peer reviewed journal dedicated to the rapid publication of studies in clinical medicine, including research on existing drugs and drugs in development across a range of therapeutic areas.... Read More

Medicine

i
Last updated on
13 Jul 2020
i
ISSN
1606-8610
i
Impact Factor
High - 1.032
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
White faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SPBASIC
i
Citation Type
Author Year
(Blonder et al, 1982)
i
Bibliography Example
Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1007/S12325-017-0478-Y
Chronic Wound Healing: A Review of Current Management and Treatments
George Han1, Roger I. Ceilley2
21 Jan 2017 - Advances in Therapy

Abstract:

Wound healing is a complex, highly regulated process that is critical in maintaining the barrier function of skin. With numerous disease processes, the cascade of events involved in wound healing can be affected, resulting in chronic, non-healing wounds that subject the patient to significant discomfort and distress while dra... Wound healing is a complex, highly regulated process that is critical in maintaining the barrier function of skin. With numerous disease processes, the cascade of events involved in wound healing can be affected, resulting in chronic, non-healing wounds that subject the patient to significant discomfort and distress while draining the medical system of an enormous amount of resources. The healing of a superficial wound requires many factors to work in concert, and wound dressings and treatments have evolved considerably to address possible barriers to wound healing, ranging from infection to hypoxia. Even optimally, wound tissue never reaches its pre-injured strength and multiple aberrant healing states can result in chronic non-healing wounds. This article will review wound healing physiology and discuss current approaches for treating a wound. read more read less

Topics:

Negative-pressure wound therapy (67%)67% related to the paper, Chronic wound (64%)64% related to the paper, Wound healing (53%)53% related to the paper
View PDF
1,112 Citations
open accessOpen access Journal Article DOI: 10.1007/S12325-013-0060-1
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
25 Oct 2013 - Advances in Therapy

Abstract:

Effective treatments for hormone-receptor-positive (HR+) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free s... Effective treatments for hormone-receptor-positive (HR+) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population. BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR+ advanced BC with recurrence/progression during or after NSAIs. The primary endpoint was PFS by local investigator review, and was confirmed by independent central radiology review. Overall survival, response rate, and clinical benefit rate were secondary endpoints. Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2 months, respectively; hazard ratio = 0.45 (95% confidence interval 0.38–0.54); log-rank P < 0.0001; central review: 11.0 versus 4.1 months, respectively; hazard ratio = 0.38 (95% confidence interval 0.31–0.48); log-rank P < 0.0001] in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, patients with recurrence during or within 12 months of completion of adjuvant therapy, and irrespective of age. The incidence and severity of adverse events were consistent with those reported at the interim analysis and in other everolimus trials. The addition of everolimus to exemestane markedly prolonged PFS in patients with HR+ advanced BC with disease recurrence/progression following prior NSAIs. These results further support the use of everolimus plus exemestane in this patient population. ClinicalTrials.gov #NCT00863655. read more read less

Topics:

Everolimus (60%)60% related to the paper, Exemestane (59%)59% related to the paper, Progression-free survival (53%)53% related to the paper, Population (52%)52% related to the paper, Interim analysis (51%)51% related to the paper
View PDF
412 Citations
Journal Article DOI: 10.1007/S12325-014-0140-X
Pathogenesis and Treatment of Impaired Wound Healing in Diabetes Mellitus: New Insights
Dimitrios Baltzis, Ioanna Eleftheriadou, Aristidis Veves1
29 Jul 2014 - Advances in Therapy

Abstract:

Diabetic foot ulcers (DFUs) are one of the most common and serious complications of diabetes mellitus, as wound healing is impaired in the diabetic foot. Wound healing is a dynamic and complex biological process that can be divided into four partly overlapping phases: hemostasis, inflammation, proliferative and remodeling. Th... Diabetic foot ulcers (DFUs) are one of the most common and serious complications of diabetes mellitus, as wound healing is impaired in the diabetic foot. Wound healing is a dynamic and complex biological process that can be divided into four partly overlapping phases: hemostasis, inflammation, proliferative and remodeling. These phases involve a large number of cell types, extracellular components, growth factors and cytokines. Diabetes mellitus causes impaired wound healing by affecting one or more biological mechanisms of these processes. Most often, it is triggered by hyperglycemia, chronic inflammation, micro- and macro-circulatory dysfunction, hypoxia, autonomic and sensory neuropathy, and impaired neuropeptide signaling. Research focused on thoroughly understanding these mechanisms would allow for specifically targeted treatment of diabetic foot ulcers. The main principles for DFU treatment are wound debridement, pressure off-loading, revascularization and infection management. New treatment options such as bioengineered skin substitutes, extracellular matrix proteins, growth factors, and negative pressure wound therapy, have emerged as adjunctive therapies for ulcers. Future treatment strategies include stem cell-based therapies, delivery of gene encoding growth factors, application of angiotensin receptors analogs and neuropeptides like substance P, as well as inhibition of inflammatory cytokines. This review provides an outlook of the pathophysiology in diabetic wound healing and summarizes the established and adjunctive treatment strategies, as well as the future therapeutic options for the treatment of DFUs. read more read less

Topics:

Negative-pressure wound therapy (60%)60% related to the paper, Diabetic foot (57%)57% related to the paper, Adjunctive treatment (57%)57% related to the paper, Wound healing (53%)53% related to the paper, Diabetes mellitus (51%)51% related to the paper
402 Citations
open accessOpen access Journal Article DOI: 10.1007/S12325-017-0612-X
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
05 Oct 2017 - Advances in Therapy

Abstract:

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intraveno... Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue. F. Hoffmann-La Roche Ltd., Basel, Switzerland. read more read less

Topics:

Obinutuzumab (64%)64% related to the paper, Rituximab (63%)63% related to the paper, Ofatumumab (62%)62% related to the paper, Mantle cell lymphoma (62%)62% related to the paper, B-cell lymphoma (58%)58% related to the paper
View PDF
360 Citations
open accessOpen access Journal Article DOI: 10.1007/S12325-018-0805-Y
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Lawrence Blonde1, Kamlesh Khunti2, Stewart B. Harris3, Casey Meizinger4, Neil Skolnik
24 Oct 2018 - Advances in Therapy

Abstract:

Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice. While randomized clinical trials (RCTs) are the "gold standard" for evaluating the safety and efficacy of new therapeutic agents, necessarily strict inclusion and exclusion criteria mean that trial popu... Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice. While randomized clinical trials (RCTs) are the "gold standard" for evaluating the safety and efficacy of new therapeutic agents, necessarily strict inclusion and exclusion criteria mean that trial populations are often not representative of the patient populations encountered in clinical practice. Real-world studies may use information from electronic health and claims databases, which provide large datasets from diverse patient populations, and/or may be observational, collecting prospective or retrospective data over a long period of time. They can therefore provide information on the long-term safety, particularly pertaining to rare events, and effectiveness of drugs in large heterogeneous populations, as well as information on utilization patterns and health and economic outcomes. This review focuses on how evidence from real-world studies can be utilized to complement data from RCTs to gain a more complete picture of the advantages and disadvantages of medications as they are used in practice.Funding: Sanofi US, Inc. read more read less

Topics:

Evidence-based medicine (56%)56% related to the paper, Randomized controlled trial (53%)53% related to the paper, Observational study (51%)51% related to the paper
View PDF
354 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Advances in Therapy.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Advances in Therapy format uses SPBASIC citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Advances in Therapy in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Advances in Therapy guidelines and auto format it.

2. Do you follow the Advances in Therapy guidelines?

Yes, the template is compliant with the Advances in Therapy guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Advances in Therapy?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Advances in Therapy citation style.

4. Can I use the Advances in Therapy templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Advances in Therapy.

5. Can I use a manuscript in Advances in Therapy that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Advances in Therapy that you can download at the end.

6. How long does it usually take you to format my papers in Advances in Therapy?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Advances in Therapy.

7. Where can I find the template for the Advances in Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Advances in Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Advances in Therapy's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Advances in Therapy an online tool or is there a desktop version?

SciSpace's Advances in Therapy is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Advances in Therapy?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Advances in Therapy?”

11. What is the output that I would get after using Advances in Therapy?

After writing your paper autoformatting in Advances in Therapy, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Advances in Therapy's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Advances in Therapy?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Advances in Therapy. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Advances in Therapy?

The 5 most common citation types in order of usage for Advances in Therapy are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Advances in Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Advances in Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Advances in Therapy in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Advances in Therapy Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Advances in Therapy formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template